Chinese biopharmaceutical firm CARsgen bags $186m Series C led by Loyal Valley

Chinese biopharmaceutical firm CARsgen bags $186m Series C led by Loyal Valley

Photo by Brett Jordan on Unsplash

Clinical-stage immune-oncology therapy developer CARsgen Therapeutics Holdings Limited announced on Monday that it has secured $186 million in a Series C round financing led by Loyal Valley Capital.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter